Trial · NCT04632589
Losartan for Improved Vascular Endothelial Function After Preeclampsia
NCT04632589, Early phase 1, Completed, Anna Stanhewicz, PhD; results first posted 2025-07-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Losartan for Improved Vascular Endothelial Function After Preeclampsia. Trials, record NCT04632589. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04632589
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Losartan for Improved Vascular Endothelial Function After Preeclampsia
- NCT number
- NCT04632589
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 11 participants, actual
- Lead sponsor
- Anna Stanhewicz, PhD
- Conditions
- Preeclampsia Postpartum
- Interventions
- Losartan Potassium, Placebo
- First posted
- 2020-11-17
- Last updated
- 2025-07-10
- Results first posted
- 2025-07-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cutaneous Conductance (%Maximum) Response to Acetylcholine | immediately following 6 weeks of oral treatment (losartan or placebo) | Cutaneous vascular vasodilator response to exogenous acetylcholine perfusion; measured with laser-Doppler flowmetry during intradermal microdialysis delivery of acetylcholine alone or co-infused with L-NAME. Cutaneous conductance is calculated (laser-Doppler flux/mean arterial pressure) and normalized to site specific maximal dilation (%maximum). |
| Primary | Cutaneous Conductance (%Baseline) Response to Angiotensin II | immediately following 6 weeks of oral treatment (losartan or placebo) | Cutaneous vascular constrictor response to exogenous ang II perfusion; measured by laser-Doppler flowmetry during intradermal microdialysis delivery of angiotensin II. Cutaneous conductance is calculated (laser-Doppler flux/mean arterial pressure) and normalized to site-specific baseline conductance (%baseline) measured on the study day before the perfusion of angiotensin II. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cutaneous Conductance (%Maximum) Response to Acetylcholine | immediately following 6 weeks of oral treatment (losartan or placebo) | All participants completed both treatments in randomized, blinded, cross-over design | % of maximal cutaneous conductance | MEAN |
| PRIMARY | Cutaneous Conductance (%Baseline) Response to Angiotensin II | immediately following 6 weeks of oral treatment (losartan or placebo) | all participants completed both treatments in randomized, blinded, cross-over design | % of baseline cutaneous conductance | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cutaneous Conductance (%Maximum) Response to Acetylcholine | Losartan | 89.4 | Standard Deviation 22.6 | % of maximal cutaneous conductance | |
| Cutaneous Conductance (%Maximum) Response to Acetylcholine | Placebo | 72.5 | Standard Deviation 16.5 | % of maximal cutaneous conductance | |
| Cutaneous Conductance (%Baseline) Response to Angiotensin II | Losartan | 76.7 | Standard Deviation 29.1 | % of baseline cutaneous conductance | |
| Cutaneous Conductance (%Baseline) Response to Angiotensin II | Placebo | 53.8 | Standard Deviation 27.3 | % of baseline cutaneous conductance |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Losartan Than Placebo | 6 | |
| Overall Study | STARTED | Placebo Than Losartan | 5 | |
| Overall Study | COMPLETED | Losartan Than Placebo | 6 | |
| Overall Study | COMPLETED | Placebo Than Losartan | 5 | |
| Overall Study | NOT COMPLETED | Losartan Than Placebo | 0 | |
| Overall Study | NOT COMPLETED | Placebo Than Losartan | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Losartan | 0 | 11 |
| Total, all-cause mortality | Placebo | 0 | 11 |
| Total, other adverse events | Losartan | 0 | 11 |
| Total, other adverse events | Placebo | 0 | 11 |
| Total, serious adverse events | Losartan | 0 | 11 |
| Total, serious adverse events | Placebo | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Losartan vs Placebo: deaths from any cause | Trial comparisons |
| Losartan vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04632589
GET https://conductscience.org/api/trials/v1/NCT04632589/registered